Table 2:
Efficacy Outcomes
| No. of patients (%) | |
|---|---|
| Best Overall Response (n=14) | |
| Complete Response | 0 |
| Partial Response | 0 |
| Stable Disease | 13 (92.9%) |
| Progression of Disease | 1 (7.1%) |
| Median PFS (months, 95% CI) (n=14) | 9.7 (3.8–11.8) |
| Median OS (months, 95%CI) (n=14) | 18.0 (11.8–29.9) |
| Reasons for Discontinuation (n=16) | |
| Progression of disease | 10 (62.5%) |
| Toxicity | 2 (12.5%) |
| Refusal of further treatment | 4 (25%) |
PFS, Progression-free survival
OS, Overall survival